ACM
BMY icon

Advent Capital Management’s Bristol-Myers Squibb BMY Stock Holding History

Advent Capital Management’s Portfolio BMY Stock Details BMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-300
Closed -$35K – 461
2016
Q1 		$35K Buy
+300
New +$18.9K ﹤0.01% 386
2015
Q4 		– Sell
-250
Closed -$17K – 472
2015
Q3 		$17K Buy
+250
New +$15.9K ﹤0.01% 471
2015
Q2 		– Sell
-750
Closed -$6K – 522
2015
Q1 		$6K Buy
750
+19
+3% +$1.19K ﹤0.01% 456
2014
Q4 		$10K Buy
+731
New +$41.2K ﹤0.01% 461

Other funds holding BMY

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Advent Capital Management's BMY Position: Q4 2025 in Review

Advent Capital Management sold out of Bristol-Myers Squibb (BMY) in Q4 2025, closing a stake of 75,000 shares — an estimated $3.38M sold.

Advent Capital Management first reported a position in BMY in Q1 2016 and held it in 9 quarters. The position peaked at $6.94M in Q1 2017. 2,451 funds tracked by Wall St. Rank hold BMY as of Q4 2025.

  • Advent Capital Management reported no remaining Bristol-Myers Squibb position as of Q4 2025 after selling out during the quarter.
  • Advent Capital Management sold 75,000 Bristol-Myers Squibb shares in Q4 2025, an estimated $3.38M.
  • Advent Capital Management first reported a position in Bristol-Myers Squibb in Q1 2016 and held it in 9 quarters.
  • Advent Capital Management's Bristol-Myers Squibb position peaked at $6.94M in Q1 2017.
  • 2,451 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q4 2025.

Based on Advent Capital Management's 13F filing for Q4 2025, filed 9 Feb 2026.